Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Inventory (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Inventory for 6 consecutive years, with $17.9 million as the latest value for Q3 2018.

  • Quarterly Inventory rose 17.47% to $17.9 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $17.9 million through Sep 2018, up 17.47% year-over-year, with the annual reading at $16.8 million for FY2017, 37.73% up from the prior year.
  • Inventory for Q3 2018 was $17.9 million at Theravance Biopharma, roughly flat from $17.9 million in the prior quarter.
  • The five-year high for Inventory was $17.9 million in Q3 2018, with the low at $9.4 million in Q1 2016.
  • Average Inventory over 5 years is $13.4 million, with a median of $12.5 million recorded in 2014.
  • The sharpest move saw Inventory fell 23.76% in 2016, then soared 47.67% in 2018.
  • Over 5 years, Inventory stood at $12.5 million in 2014, then decreased by 20.25% to $10.0 million in 2015, then rose by 22.14% to $12.2 million in 2016, then skyrocketed by 37.73% to $16.8 million in 2017, then increased by 6.49% to $17.9 million in 2018.
  • According to Business Quant data, Inventory over the past three periods came in at $17.9 million, $17.9 million, and $17.2 million for Q3 2018, Q2 2018, and Q1 2018 respectively.